Conv. Plasma
Nigella Sativa

All vitamin D studies
Meta analysis
study COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case 34% Improvement Relative Risk Vitamin D for COVID-19  Bhat et al.  Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Prospective study of 580 patients in India Fewer symptomatic cases with vitamin D (p=0.011) Bhat et al., J. Infection, March 2023 Favors vitamin D Favors control

Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial

Bhat et al., Journal of Infection, doi:10.1016/j.jinf.2023.03.004, CTRI/2021/08/035709
Mar 2023  
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Prospective study of 580 ChAdOx1 recipients, 262 treated with calcifediol (patient choice), showing lower cases with treatment. Supplementation did not significantly affect antibody levels following ChAdOx1 receipt. Calcifediol patients were older (31 vs. 26 in the exposed subgroup containing most patients). 50μg/day calcifediol.
This is the 108th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).
29 studies are RCTs, which show efficacy with p=0.0000024.
risk of symptomatic case, 34.2% lower, RR 0.66, p = 0.01, treatment 59 of 262 (22.5%), control 52 of 152 (34.2%), NNT 8.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bhat et al., 6 Mar 2023, prospective, placebo-controlled, India, peer-reviewed, 13 authors, dosage calcifediol 50μg days 1-180, trial CTRI/2021/08/035709.
This PaperVitamin DAll
Abstract: Journal of Infection xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Journal of Infection journal homepage: Letter to the Editor Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial Dear Editor, Coronavirus disease 2019 (COVID-19) has caused formidable global health crisis, and multiple vaccination programs have been rolled out to curb the spread of the pandemic. Genetic disorders like primary immunodeficiency diseases severely compromise the gen­ eration of protective immunity following vaccinations. The spectrum also includes those genetic disorders that have a lesser impact on immunological memory such as Down Syndrome (DS). In a recent study, Valentini et al.1 confirmed that the serological efficacy of COVID-19 vaccination is least affected by DS. The authors included a substantial number of subjects and further observed that the older subjects exhibit lower anti-SARS-CoV-2 antibody titers 6 months after vaccination. Earlier, Yarci-Carrion et al.2 had also reported that DS and non-DS subjects develop similar anti-SARS-CoV-2 titers after the third dose of vaccine that decline with age. However, the same group demonstrated that DS subjects develop milder T cell responses to the standard 2-dose vaccine.3 Valentini et al.1 further denote that the factors modifying immune responses to vaccination in such disorders are less explored. This may include nutritional deficiencies like vitamin D [25(OH)D]. Indeed, reports have shown that hypovi­ taminosis D is quite frequent in subjects with DS.4 It is also known that individuals with low 25(OH)D levels have a higher risk of acquiring severe COVID-19 and stimulation of vitamin D receptor can reduce COVID-19-associated hospitalization and mortality.5,6 However, studies on vitamin D supplementation in COVID-19 vaccination have yielded conflicting results with some reporting improvement, while others observing lack of association between 25(OH)D status and antibody titers post vaccination.7,8 Most of these studies, however, did not assess cellular immune re­ sponses, which are more likely to be influenced by vitamin D. Cal­ cifediol [25(OH)D3], the immediate precursor of 1,25(OH)2D3 leads to a faster achievement of desired levels and biodistribution of cir­ culating 1,25(OH)2D3 as compared to cholecalciferol (vitamin D3).9 There are reports on favorable outcomes of calcifediol supple­ mentation in COVID-19,10 but there are no data on its utility in im­ proving efficacy of COVID-19 vaccines. Therefore, we evaluated the efficacy of calcifediol supplementation on cell-mediated immune responses besides anti-SARS-CoV-2 titers post COVID-19 vaccina­ tion. We carried an open-label, placebo-controlled clinical trial to assess the impact of calcifediol supplementation on the efficacy of ChAdOx1 nCoV-19 vaccine in terms of, protection from break­ through infection and COVID-19 disease, anti-SARS-CoV-2 antibody titers, SARS-CoV-2 specific lymphocyte proliferation and cytokine secretion. Herein 580 adult subjects receiving ChAdOx1 nCoV-19 vaccine were recruited at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The subjects received either calcifediol (50 µg/day) or placebo, orally for 6 months (Supplementary Fig. 1, Supplementary Table 1) and divided in 3 groups [SARS-CoV-2 unexposed,..
{ 'DOI': '10.1016/j.jinf.2023.03.004', 'ISSN': ['0163-4453'], 'URL': '', 'alternative-id': ['S0163445323001317'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Effect of calcifediol supplementation as add-on therapy on the immune ' 'repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective ' 'open-label, placebo-controlled, clinical trial'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'Journal of Infection'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': ''}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2023 The British Infection Association. Published by Elsevier Ltd. All rights ' 'reserved.'}], 'author': [ {'affiliation': [], 'family': 'Bhat', 'given': 'Swati', 'sequence': 'first'}, {'affiliation': [], 'family': 'Das', 'given': 'Liza', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Maheshwari', 'given': 'Deep', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Badal', 'given': 'Darshan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sarkar', 'given': 'Roman', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Gupta', 'given': 'Madhu', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pandav', 'given': 'Surinder Singh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Padhi', 'given': 'Bijaya Kumar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bhadada', 'given': 'Sanjay Kumar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Holick', 'given': 'Michael F.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Dutta', 'given': 'Pinaki', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sachdeva', 'given': 'Naresh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Marwaha', 'given': 'Raman Kumar', 'sequence': 'additional'}], 'container-title': 'Journal of Infection', 'container-title-short': 'Journal of Infection', 'content-domain': { 'crossmark-restriction': True, 'domain': [ '', '', '', '', '', '', '', '']}, 'created': {'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T20:58:46Z', 'timestamp': 1678136326000}, 'deposited': { 'date-parts': [[2023, 3, 12]], 'date-time': '2023-03-12T12:02:53Z', 'timestamp': 1678622573000}, 'indexed': {'date-parts': [[2023, 3, 13]], 'date-time': '2023-03-13T04:33:29Z', 'timestamp': 1678682009291}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2023, 3]]}, 'language': 'en', 'license': [ { 'URL': '', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 3, 1]], 'date-time': '2023-03-01T00:00:00Z', 'timestamp': 1677628800000}}], 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'prefix': '10.1016', 'published': {'date-parts': [[2023, 3]]}, 'published-print': {'date-parts': [[2023, 3]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'article-title': 'Factor associated with SARS-CoV-2 vaccination serological efficacy in ' 'adolescents and adults with Down syndrome: data from an international, ' 'collaborative initiative of the Trisomy 21 Research Society', 'author': 'Valentini', 'first-page': '00090', 'issue': '23', 'journal-title': 'J Infect', 'key': '10.1016/j.jinf.2023.03.004_bib1', 'volume': '4453', 'year': '2023'}, { 'DOI': '10.1016/j.jinf.2022.11.014', 'article-title': 'Effect of a SARS-CoV-2 booster vaccine dose on the immune response of ' 'adults with Down syndrome', 'author': 'Yarci-Carrión', 'doi-asserted-by': 'crossref', 'first-page': '154', 'issue': '2', 'journal-title': 'J Infect', 'key': '10.1016/j.jinf.2023.03.004_bib2', 'volume': '86', 'year': '2023'}, { 'DOI': '10.1093/cid/ciac590', 'article-title': 'Development of an effective immune response in adults with down ' 'syndrome after severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2) vaccination', 'author': 'Esparcia-Pinedo', 'doi-asserted-by': 'crossref', 'first-page': 'e155', 'issue': '3', 'journal-title': 'Clin Infect Dis', 'key': '10.1016/j.jinf.2023.03.004_bib3', 'volume': '76', 'year': '2023'}, { 'DOI': '10.1155/2015/896758', 'article-title': 'Determinants of vitamin D levels in children and adolescents with Down ' 'syndrome', 'author': 'Stagi', 'doi-asserted-by': 'crossref', 'first-page': '896758', 'journal-title': 'Int J Endocrinol', 'key': '10.1016/j.jinf.2023.03.004_bib4', 'volume': '2015', 'year': '2015'}, { 'DOI': '10.3390/nu14245329', 'article-title': 'The impact of serum levels of vitamin D3 and its metabolites on the ' 'prognosis and disease severity of COVID-19', 'author': 'Fabbri', 'doi-asserted-by': 'crossref', 'first-page': '5329', 'journal-title': 'Nutrients', 'key': '10.1016/j.jinf.2023.03.004_bib5', 'volume': '14', 'year': '2022'}, { 'DOI': '10.1016/j.jsbmb.2020.105719', 'article-title': 'Vitamin D receptor stimulation to reduce acute respiratory distress ' 'syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: ' 'revised Ms SBMB 2020_166', 'author': 'Quesada-Gomez', 'doi-asserted-by': 'crossref', 'journal-title': 'J Steroid Biochem Mol Biol', 'key': '10.1016/j.jinf.2023.03.004_bib6', 'volume': '202', 'year': '2020'}, { 'DOI': '10.3390/nu14183821', 'article-title': 'Vitamin D supplementation does not influence SARS-CoV-2 vaccine ' 'efficacy or immunogenicity: sub-studies nested within the CORONAVIT ' 'randomised controlled trial', 'author': 'Jolliffe', 'doi-asserted-by': 'crossref', 'first-page': '3821', 'issue': '18', 'journal-title': 'Nutrients', 'key': '10.1016/j.jinf.2023.03.004_bib7', 'volume': '14', 'year': '2022'}, { 'DOI': '10.1016/j.retram.2022.103344', 'article-title': 'Age and vitamin D affect the magnitude of the antibody response to the ' 'first dose of the SARS-CoV-2 BNT162b2 vaccine', 'author': 'Piec', 'doi-asserted-by': 'crossref', 'issue': '3', 'journal-title': 'Curr Res Transl Med', 'key': '10.1016/j.jinf.2023.03.004_bib8', 'volume': '70', 'year': '2022'}, { 'DOI': '10.1002/jbmr.4387', 'article-title': 'Calcifediol is superior to cholecalciferol in improving vitamin D ' 'status in postmenopausal women: a randomized trial', 'author': 'Pérez-Castrillón', 'doi-asserted-by': 'crossref', 'first-page': '1967', 'issue': '10', 'journal-title': 'J Bone Miner Res', 'key': '10.1016/j.jinf.2023.03.004_bib9', 'volume': '36', 'year': '2021'}, { 'DOI': '10.1016/j.nut.2022.111899', 'article-title': 'REsCue trial: randomized controlled clinical trial with ' 'extended-release calcifediol in symptomatic COVID-19 outpatients', 'author': 'Bishop', 'doi-asserted-by': 'crossref', 'journal-title': 'Nutrition', 'key': '10.1016/j.jinf.2023.03.004_bib10', 'volume': '107', 'year': '2023'}], 'reference-count': 10, 'references-count': 10, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients ' 'of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial', 'type': 'journal-article', 'update-policy': ''}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop